fluoxetine and quinidine

fluoxetine has been researched along with quinidine in 42 studies

Research

Studies (42)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (7.14)	18.2507
2000's	18 (42.86)	29.6817
2010's	20 (47.62)	24.3611
2020's	1 (2.38)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Dormann, SM; Haefeli, WE; Kerpen, CJ; Ketabi-Kiyanvash, N; Martin-Facklam, M; Weiss, J	1
Keserü, GM	1
Nagashima, R; Nishikawa, T; Tobita, M	1
Engel, K; Wang, J	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Abraham, MH; Acree, WE; Ibrahim, A	1
Jia, L; Sun, H	1
Curcio, R; Nicoli, R; Rudaz, S; Veuthey, JL	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
García-Mera, X; González-Díaz, H; Prado-Prado, FJ	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Glen, RC; Lowe, R; Mitchell, JB	1
Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ	1
Ekins, S; Williams, AJ; Xu, JJ	1
Claxton, CR; Curran, RE; Harradine, PJ; Hutchison, L; Littlewood, P; Martin, IJ	1
Balani, SK; Gan, LS; Li, P; Lu, C	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Cheon, SH; Choi, K; Hahn, HG; Han, M; Song, C; Yun, J	1
Hahn, HG; Han, M; Jeong, N; Song, C	1
Cho, H; Elkamhawy, A; Heo, JC; Kim, HY; Kim, KH; Lee, CO; Nam, DH; Pae, AN; Park, WK; Roh, EJ; Seol, HJ; Viswanath, AN; Yang, H	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Wang, J	1
Stevens, JC; Wrighton, SA	1
Belpaire, FM; Brøsen, K; Rasmussen, BB; Temmerman, A; Wijnant, P	1
Lurcott, G	1
Ekins, S; Mankowski, DC; Margolis, JM; O'Donnell, JP; Obach, RS	1
Fernandes, LC; Kaplan, HL; Kilicarslan, T; Romach, MK; Sellers, EM; Tyndale, RF	1
Bertelsen, KM; Greenblatt, DJ; Obach, RS; Venkatakrishnan, K; Von Moltke, LL	1
Margolis, JM; Obach, RS	1
Engel, AG; Fukodome, T; Harper, CM	1
Haining, RL; Yu, AM	1
Guo, B; He, MM; Li, C; Liu, H; Shen, H; Wang, L; Wrighton, SA	1
Ewald, AH; Maurer, HH	1
Castberg, I; Davies, SJ; Lennard, MS; Lewis, G; Spigset, O; Taylor, S; Westin, AA	1
Gouda, H; Handa, K; Hirono, S; Nakagome, I; Yamaotsu, N	1
Beeson, D; Lee, M; Palace, J	1
Ahemad, N; Dong, AN; Ong, CE; Palanisamy, UD; Pan, Y; Yiap, BC	1

Reviews

4 review(s) available for fluoxetine and quinidine

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
The plasma membrane monoamine transporter (PMAT): Structure, function, and role in organic cation disposition. Clinical pharmacology and therapeutics, 2016, Volume: 100, Issue:5 Topics: Animals; Biogenic Amines; Humans; Plasma Membrane Neurotransmitter Transport Proteins; Xenobiotics	2016
The effects of the genetic absence and inhibition of CYP2D6 on the metabolism of codeine and its derivatives, hydrocodone and oxycodone. Anesthesia progress, 1998,Fall, Volume: 45, Issue:4 Topics: Analgesics, Opioid; Anti-Arrhythmia Agents; Binding, Competitive; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Enzyme Inhibitors; Fluoxetine; Humans; Hydrocodone; Oxycodone; Paroxetine; Quinidine; Selective Serotonin Reuptake Inhibitors	1998
Therapeutic strategies for congenital myasthenic syndromes. Annals of the New York Academy of Sciences, 2018, Volume: 1412, Issue:1 Topics: Adrenergic beta-Agonists; Breast Feeding; Cholinergic Antagonists; Cholinesterase Inhibitors; Female; Fluoxetine; Humans; Infant; Infant, Newborn; Mutation; Myasthenic Syndromes, Congenital; Neuromuscular Junction; Pregnancy; Pregnancy Complications; Quinidine; Receptors, Cholinergic	2018

Trials

1 trial(s) available for fluoxetine and quinidine

Article	Year
Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:3 Topics: Adult; Aged; Analgesics, Opioid; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Double-Blind Method; Enzyme Inhibitors; Female; Fluoxetine; Humans; Male; Middle Aged; Pilot Projects; Quinidine; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders	2002

Article

Year

Treatment of codeine dependence with inhibitors of cytochrome P450 2D6.

Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:3

Topics: Adult; Aged; Analgesics, Opioid; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Double-Blind Method; Enzyme Inhibitors; Female; Fluoxetine; Humans; Male; Middle Aged; Pilot Projects; Quinidine; Selective Serotonin Reuptake Inhibitors; Substance-Related Disorders

2002

Other Studies

37 other study(ies) available for fluoxetine and quinidine

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Inhibition of P-glycoprotein by newer antidepressants. The Journal of pharmacology and experimental therapeutics, 2003, Volume: 305, Issue:1 Topics: Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Endothelium, Vascular; Humans; Reproducibility of Results; Swine; Transfection	2003
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods. Bioorganic & medicinal chemistry letters, 2003, Aug-18, Volume: 13, Issue:16 Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship	2003
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors. Bioorganic & medicinal chemistry letters, 2005, Jun-02, Volume: 15, Issue:11 Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated	2005
Interaction of organic cations with a newly identified plasma membrane monoamine transporter. Molecular pharmacology, 2005, Volume: 68, Issue:5 Topics: 1-Methyl-4-phenylpyridinium; Animals; Biological Transport; Cell Line; Dogs; Equilibrative Nucleoside Transport Proteins; Humans; Membrane Transport Proteins; Nerve Tissue Proteins; Organic Cation Transport Proteins; Tyramine	2005
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs. European journal of medicinal chemistry, 2008, Volume: 43, Issue:3 Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization	2008
Support vector machines classification of hERG liabilities based on atom types. Bioorganic & medicinal chemistry, 2008, Jun-01, Volume: 16, Issue:11 Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve	2008
Development of an in-capillary approach to nanoscale automated in vitro cytochromes p450 assays. Journal of medicinal chemistry, 2009, Apr-23, Volume: 52, Issue:8 Topics: Autoanalysis; Chromatography, High Pressure Liquid; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme System; Dextromethorphan; Fluoxetine; Humans; Isoenzymes; Mass Spectrometry; Pharmaceutical Preparations; Quinidine; Recombinant Proteins; Solutions; Venlafaxine Hydrochloride	2009
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species. Bioorganic & medicinal chemistry, 2010, Mar-15, Volume: 18, Issue:6 Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics	2010
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
Predicting phospholipidosis using machine learning. Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5 Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine	2010
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicological sciences : an official journal of the Society of Toxicology, 2010, Volume: 118, Issue:2 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Control and measurement of plasma pH in equilibrium dialysis: influence on drug plasma protein binding. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:3 Topics: Animals; Blood Proteins; Buffers; Carbon Dioxide; Chemical Phenomena; Dialysis; Dogs; Drug Evaluation, Preclinical; Humans; Hydrogen-Ion Concentration; Macaca fascicularis; Mice; Osmolar Concentration; Pharmaceutical Preparations; Protein Binding; Rats; Reproducibility of Results	2011
A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:6 Topics: Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Enzyme Inhibitors; High-Throughput Screening Assays; Humans; Inhibitory Concentration 50; Microsomes, Liver; Time Factors	2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment. Journal of applied toxicology : JAT, 2012, Volume: 32, Issue:10 Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers	2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Synthesis and biological evaluation of 3-phenethylazetidine derivatives as triple reuptake inhibitors. Bioorganic & medicinal chemistry letters, 2014, Aug-01, Volume: 24, Issue:15 Topics: Azetidines; Biological Transport; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Neurotransmitter Uptake Inhibitors; Phenyl Ethers; Plasma Membrane Neurotransmitter Transport Proteins; Serotonin; Structure-Activity Relationship	2014
Exploration of 3-Aminoazetidines as Triple Reuptake Inhibitors by Bioisosteric Modification of 3-α-Oxyazetidine. ACS medicinal chemistry letters, 2014, Sep-11, Volume: 5, Issue:9 Topics:	2014
Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). European journal of medicinal chemistry, 2015, Oct-20, Volume: 103 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dacarbazine; Dose-Response Relationship, Drug; Drug Discovery; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Glioblastoma; Humans; Models, Molecular; Molecular Conformation; Quinazolines; Structure-Activity Relationship; Temozolomide; Urea	2015
Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. The Journal of pharmacology and experimental therapeutics, 1993, Volume: 266, Issue:2 Topics: Animals; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dealkylation; Fluoxetine; Humans; Kinetics; Liver; Male; Mixed Function Oxygenases; Quinidine; Rats; Rats, Sprague-Dawley; Stereoisomerism	1993
The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. European journal of clinical pharmacology, 1998, Volume: 54, Issue:3 Topics: 1-Naphthylamine; Adult; Anti-Arrhythmia Agents; Child; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Kinetics; Male; Methylation; Metoprolol; Microsomes, Liver; Oxidation-Reduction; Paroxetine; Quinidine; Selective Serotonin Reuptake Inhibitors; Sertraline	1998
(R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. Drug metabolism and disposition: the biological fate of chemicals, 2000, Volume: 28, Issue:10 Topics: Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Fluoxetine; Humans; Isoenzymes; Ketoconazole; Kinetics; Methylation; Microsomes, Liver; Quinidine; Recombinant Proteins; Selective Serotonin Reuptake Inhibitors; Stereoisomerism; Sulfaphenazole	2000
Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine. Drug metabolism and disposition: the biological fate of chemicals, 2003, Volume: 31, Issue:3 Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dose-Response Relationship, Drug; Enzyme Inhibitors; Fluoxetine; Humans; Microsomes, Liver; Paroxetine; Quinidine	2003
Impact of nonspecific binding to microsomes and phospholipid on the inhibition of cytochrome P4502D6: implications for relating in vitro inhibition data to in vivo drug interactions. Drug metabolism and disposition: the biological fate of chemicals, 2003, Volume: 31, Issue:5 Topics: Benzylamines; Bridged Bicyclo Compounds, Heterocyclic; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Drug Interactions; Enzyme Inhibitors; Ethanolamines; Fluoxetine; Humans; Imipramine; In Vitro Techniques; Microsomes; Phospholipids; Protein Binding; Quinidine	2003
Treatment of slow-channel congenital myasthenic syndrome with fluoxetine. Neurology, 2003, May-27, Volume: 60, Issue:10 Topics: Adult; Cholinergic Antagonists; Drug Evaluation; Drug Hypersensitivity; Female; Fluoxetine; Genes, Dominant; Humans; Mutation, Missense; Myasthenic Syndromes, Congenital; Point Mutation; Quinidine; Receptors, Cholinergic; Treatment Outcome	2003
Expression, purification, and characterization of mouse CYP2d22. Drug metabolism and disposition: the biological fate of chemicals, 2006, Volume: 34, Issue:7 Topics: Amino Acid Sequence; Animals; Baculoviridae; Cell Line; Cloning, Molecular; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Cytochrome P450 Family 2; Dealkylation; Dextromethorphan; Enzyme Inhibitors; Fluoxetine; Insecta; Ketoconazole; Kinetics; Methadone; Mice; Molecular Sequence Data; Molecular Weight; Quinidine; Sequence Homology, Amino Acid; Substrate Specificity	2006
Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug metabolism and disposition: the biological fate of chemicals, 2007, Volume: 35, Issue:8 Topics: Atomoxetine Hydrochloride; Cocaine; Codeine; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Debrisoquin; Dextromethorphan; Enzyme Inhibitors; Ethanolamines; Fluoxetine; Humans; Hydroxylation; Imipramine; Kinetics; Microsomes; Molecular Structure; Nortriptyline; Polymorphism, Single Nucleotide; Propylamines; Quinidine; Recombinant Proteins; Thioridazine; Tramadol	2007
2,5-Dimethoxyamphetamine-derived designer drugs: studies on the identification of cytochrome P450 (CYP) isoenzymes involved in formation of their main metabolites and on their capability to inhibit CYP2D6. Toxicology letters, 2008, Dec-15, Volume: 183, Issue:1-3 Topics: Algorithms; Amphetamines; Animals; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Designer Drugs; DOM 2,5-Dimethoxy-4-Methylamphetamine; Fluoxetine; Gas Chromatography-Mass Spectrometry; Humans; Hydroxylation; Insecta; Kinetics; Microsomes, Liver; Molecular Structure; Quinidine; Spectrometry, Mass, Electrospray Ionization	2008
Characterisation of zuclopenthixol metabolism by in vitro and therapeutic drug monitoring studies. Acta psychiatrica Scandinavica, 2010, Volume: 122, Issue:6 Topics: Adult; Antidepressive Agents, Second-Generation; Antifungal Agents; Antimalarials; Antimanic Agents; Antipsychotic Agents; Carbamazepine; Clopenthixol; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Female; Fluoxetine; Humans; In Vitro Techniques; Ketoconazole; Male; Methotrimeprazine; Microsomes, Liver; Middle Aged; Paroxetine; Quinidine	2010
In silico study on the inhibitory interaction of drugs with wild-type CYP2D6.1 and the natural variant CYP2D6.17. Drug metabolism and pharmacokinetics, 2014, Volume: 29, Issue:1 Topics: Cocaine; Computer Simulation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Enzyme Inhibitors; Fluoxetine; Imipramine; Molecular Docking Simulation; Molecular Dynamics Simulation; Organic Chemicals; Polymorphism, Genetic; Protein Conformation; Quinidine; Regression Analysis; Stereoisomerism; Thioridazine	2014
Role of P34S, G169R, R296C, and S486T Substitutions in Ligand Access and Catalysis for Cytochrome P450 2D6 Allelic Variants CYP2D614A and CYP2D614B. Drug metabolism and bioanalysis letters, 2022, Volume: 15, Issue:1 Topics: Alleles; Catalysis; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme System; Fluoxetine; Ligands; Molecular Docking Simulation; Paroxetine; Quinidine; Terbinafine	2022